Pacific Biometrics' Chief Scientific Officer, Elizabeth Leary, PhD, Has Co-Authored the BONES Study Recently Published

SEATTLE, WA, Jan 22 (MARKET WIRE) --
Elizabeth Leary, PhD, the Chief Scientific Officer and co-founder of Pacific
Biometrics, Inc. (OTCBB: PBME) ("PBI"), has recently been published in the
December 2007 issue of The Journal of Clinical Endocrinology & Metabolism.
Dr. Leary co-authored the article along with international opinion leaders and
researchers in the study of osteoporosis and related musculoskeletal
diseases. The study entitled, "Effects of atorvastatin on bone in
postmenopausal
women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging
trial," was
designed to evaluate whether or not the most widely prescribed medication
used for lowering high cholesterol, atorvastatin (Lipitor(R), made by
Pfizer), had an effect on bone mineral density (BMD) or biomarkers indicative
of bone turnover. While atorvastatin has proven to be effective in improving
clinical
outcomes in patients with high cholesterol, the authors concluded that the
therapeutic doses of the drug "had no effect on bone mineral density or
biochemical indices of bone metabolism in this study, suggesting that such oral
agents are not useful in the prevention or treatment of osteoporosis."

"This study is another example of PBI's preeminent position in providing
specialty
lab testing for clinical drug development in the fields of dyslipidemia and
musculoskeletal disorders," commented Mario Ehlers, MD, PhD, PBI's Chief
Medical Officer. "This study required an unusual combination of expertise in
both lipid and bone metabolism, and I believe PBI is one of the few specialty
central labs in the world with an established reputation in both areas. We
are very pleased to have performed the efficacy testing for this trial and to
have contributed to this important publication."

About Pacific Biometrics, Inc. (PBI)

Established in 1989, PBI provides specialized central laboratory and
contract
research services to support pharmaceutical and diagnostic manufacturers
conducting
human clinical trial research. The company provides expert services in the areas
of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The
PBI laboratory is accredited by the College of American Pathologists, and
through its non-profit affiliate Pacific Biometrics Research Foundation, is one
of
only three U.S.-based members of the Centers for Disease Control (CDC)
Cholesterol
ReferenceMethod Laboratory Network. PBI's clients include many of the world's
largest
pharmaceutical, biotech, and diagnostic companies.

Pacific Biometrics also owns several patented and patent-pending
technologies, including
monitoring devices for glucose and changes in bone turnover, an advanced,
proprietary, isothermal DNA amplification technology, and a gene-based cell
viability
technology to distinguish live from dead cells in a broad range of diagnostic
applications.

For more information about Pacific Biometrics, visit the company's web
siteat www.pacbio.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act
of1995: This press release includes forward-looking statements including,
butnot limited to, the viability and acceptance of our products and services in
the
market. These forward-looking statements are subject to a number of risks
and uncertainties that may cause actual results to differ materially from those
described in the forward-looking statements. These risks include, but are not
limited to, our ability to bid on and win laboratory services contracts, the
success
of our marketing and business development efforts, competition in the industry,
and
our ability to manage growth, as well as the risks and other factors set
forth in our periodic filings with the U.S. Securities and Exchange Commission
(including our Form 10-KSB for the year ended June 30, 2007 and our report on
Form 10-QSB for the quarter ended September 30, 2007).

Contacts:

Pacific Biometrics, Inc.
Ron Helm
CEO
(206) 298-0068

Kari Charbonnel
(206) 298-0068

Copyright 2008, Market Wire, All rights reserved.

-0-